SM
ORKA

SG3 Management’s Oruka Therapeutics ORKA Stock Holding History

SG3 Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,142
Closed -$77.7K – 347
2022
Q3 		$77.7K Buy
3,142
+1,250
+66% +$35.3K 0.01% 235
2022
Q2 		$57K Buy
+1,892
New +$53.5K 0.01% 346

Other funds holding ORKA

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

SG3 Management's ORKA Position: Q4 2022 in Review

SG3 Management sold out of Oruka Therapeutics (ORKA) in Q4 2022, closing a stake of 3,142 shares — an estimated $77.7K sold.

SG3 Management first reported a position in ORKA in Q2 2022 and held it in 2 quarters. The position peaked at $77.7K in Q3 2022. 22 funds tracked by Wall St. Rank hold ORKA as of Q4 2022.

  • SG3 Management reported no remaining Oruka Therapeutics position as of Q4 2022 after selling out during the quarter.
  • SG3 Management sold 3,142 Oruka Therapeutics shares in Q4 2022, an estimated $77.7K.
  • SG3 Management first reported a position in Oruka Therapeutics in Q2 2022 and held it in 2 quarters.
  • SG3 Management's Oruka Therapeutics position peaked at $77.7K in Q3 2022.
  • 22 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2022.

Based on SG3 Management's 13F filing for Q4 2022, filed 14 Feb 2023.